MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Control of human mesothelin-expressing tumors by DNA vaccines

Gene Therapy (2007) 14, 1189–1198; doi:10.1038/sj.gt.3302974; published online 21 June 2007. [Link]

Chang CL, Wu TC, Hung CF.

Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.

Abstract

Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma and pancreatic adenocarcinoma. In the current study, we utilized a DNA vaccine encoding human mesothelin (pcDNA3-Hmeso) to treat C57BL/6 mice challenged with luciferase-expressing, Hmeso-expressing ovarian cancer cell line, Defb29 Vegf-luc/Hmeso. The therapeutic effect of the tumor-challenged mice was followed by noninvasive bioluminescence imaging systems. The mechanism of the antitumor effect was characterized by depletion of subsets of lymphocytes as well as adopted transfer of serum from pcDNA3-Hmeso-vaccinated mice. We found that vaccination with pcDNA3-Hmeso DNA vaccine generates a significant antitumor effect and promotes survival in mice challenged with Defb29 Vegf-luc/Hmeso. Furthermore, we found CD4+ and CD8+ T-cell immune responses as well as the humoral immune responses are important for the observed antitumor effects in vaccinated mice. Our data indicated that vaccination with DNA vaccine targeting Hmeso could generate potent antitumor effects against mesothelin-expressing tumors through both T cell-mediated immunity as well as antibody-mediated immunity.

Keywords: ovarian cancer, adoptive serum transfer, human mesothelin-specific antibodies, DNA vaccine

Both comments and trackbacks are currently closed.